Verve Therapeutics, Inc., a clinical-stage biotechnology company specializing in gene-editing therapies for cardiovascular diseases, has implemented a retention bonus program for key executives amid its pending acquisition by Eli Lilly and Company. On July 14, 2025, Verve granted retention awards of $499,200 to Chief Financial Officer Allison Dorval and $416,000 to Chief Operating Officer and General Counsel Andrew Ashe. These awards are set to be paid in full on the 12-month anniversary of the acquisition’s closing date, contingent upon the executives’ continued employment through that period. In the event of termination without cause post-closing, Ashe would receive the full unpaid portion of his retention payment immediately, while Dorval would receive 50% of her unpaid retention payment upon termination, with the remaining 50% payable on the original payment date. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1840574/000119312525159005/d28638d8k.htm?utm_source=openai))
This retention program aligns with Verve’s preparations for its proposed merger with Eli Lilly, as detailed in the merger agreement dated June 16, 2025. Under the terms of the agreement, Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash, totaling approximately $1.0 billion, with the potential for an additional $3.00 per share through a contingent value right, bringing the total potential consideration to up to $1.3 billion. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, including the tender of a majority of Verve’s outstanding common stock. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-verve-therapeutics-advance-one-time-treatments?utm_source=openai))
Verve’s lead program, VERVE-102, is an in vivo gene-editing therapy targeting the PCSK9 gene, associated with cholesterol regulation. The therapy aims to provide a one-time treatment for lowering low-density lipoprotein cholesterol (LDL-C), a major factor in atherosclerotic cardiovascular disease. Phase 1b data indicated a 53% mean reduction in LDL-C at the highest dose, with no serious adverse events reported. The therapy has received Fast Track designation from the FDA, with plans for Phase 2 trials in 2026. ([ainvest.com](https://www.ainvest.com/news/eli-lilly-verve-acquisition-bold-leap-gene-editing-cardiovascular-future-2506/?utm_source=openai))
The acquisition reflects Eli Lilly’s strategic focus on expanding its capabilities in gene-editing and precision medicine, particularly in the cardiovascular health sector. By integrating Verve’s innovative therapies, Lilly aims to address the significant unmet needs in treating chronic cardiovascular conditions. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-acquire-gene-editing-therapy-developer-verve-therapeutics-up-13-2025-06-17/?utm_source=openai))
As of July 15, 2025, Verve Therapeutics’ stock is trading at $11.015 per share, with a market capitalization of approximately $405.8 million. Eli Lilly’s stock is trading at $769.66 per share.